Cycle on Sep 14, 2026

I will begin by listing the active threads and watches for this topic to understand what has already been flagged for follow-up or monitoring in past cycles.

I will check the existing notes for this topic using `read_notes` to understand what stories are already being tracked and what their exact slugs are.

I see several active watches and notes. Let's look at the active watches that might have updates around this time: - Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout (due Q3 2026) - Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation (due by end of 2026) - Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts (due Q4 2026) - Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation (due Jan 1, 2027) - Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations (due end of 2026) - Kailera v. Structure Section 1782 Discovery Ruling (due end of 2026) - Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads (due end of 2026) Let's do some web searches to see what recent news is available for the core companies: - Viking Therapeutics VK2735 maintenance study readout in Q3 2026. - Structure Therapeutics aleniglipron trials. - Eli Lilly and Novo Nordisk news (pricing, lawsuits, earnings, shortages). - Amgen MariTide. - Any other GLP-1 commercial and competitive updates. Let's start by searching for Viking Therapeutics and VK2735 maintenance study or Phase 1 maintenance study results, or general Viking Therapeutics updates. Also search for general GLP-1 news in the last month or so. Let's use `web_search` with recent=true or freshness="month".

Let's search more specifically for Viking Therapeutics' press releases in Q3 2026 or announcements about VK2735. Let's do a search on `Viking Therapeutics` in general first, sorted by relevance or recent. Let's use `web_search` with a broader query.

Ah! Look at the last result: "Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout" from investing.com, and "VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3". Let's fetch that investing.com article to see what is said about the timing or details of the VK2735 Phase 1 maintenance study readout. Let's do a search or fetch for `https://www.investing.com/news/stock-market-news/viking-therapeutics-options-flow-signals-binary-event-bet-ahead-of-vk2735-readout-93CH-4894382`. Let's fetch it first. Oh, wait, is that URL fetchable? Let's check status code or do a web search first. Let's do a web search for the text of that article to see what we can find, or fetch it. Let's fetch it first.

The article is published on September 9, 2026, and mentions "the Sept. 11 expirations just two trading sessions away... traders are positioning for a binary event this week, almost certainly the 3Q26 Phase 1 subcut maintenance topline data flagged by B.Riley as 'imminent.'" Wait, today is Monday, September 14, 2026! So the Sept 11 date has passed. Let's see if Viking Therapeutics actually released the VK2735 maintenance study results around September 10 or 11, or if there has been any update. Let's do a search for Viking Therapeutics press releases or news on VK2735 around Sept 10, 11, 12, 13, 14, 2026. Let's use `web_search`.

Ah! It looks like there are articles from Stocktwits News/Articles from 1 day ago and 2 days ago discussing: - "Following the maintenance trial data readout, Viking plans to initiate pivotal late-stage trials for the oral tablet formulation of VK2735 in the second half of 2026." - "VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation" - "Viking's next key catalyst is Q3 2026 maintenance data for VK2735..." Wait, did the maintenance trial data readout actually happen, or is it still pending? Let's search for "VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation" or search for "Viking Therapeutics" press releases in September 2026 to see if they released the maintenance trial data. Or let's see if there is any other news on VKTX. Let's search for "Viking Therapeutics" "maintenance" in the last 7 days. Let's do a search.

Okay, the maintenance study readout has not happened yet (or it's extremely imminent and people are waiting on it, but as of today, Sept 14, 2026, it might be about to release or just released). Let's see if there is any press release on Viking Therapeutics' website today or if there's any other news. Let's do a search for `"Viking Therapeutics" site:prnewswire.com` or `"Viking Therapeutics" "maintenance" "results"` with freshness="day" or "week" to see if anything dropped. Let's search.

Excellent. The articles indicate that Viking Therapeutics has NOT yet reported the maintenance dosing study results, but they are expected in Q3 2026, and the options market/investors are expecting it imminently. Wait, let's look at the other core companies: - Eli Lilly and Novo Nordisk. Let's pull their latest market views to see what the numbers look like. Let's do `market_view` for LLY and NVO. Let's first call `market_view` with `kind="ticker"` and `id="LLY"`.

Wow, look at that! There's a news item from September 12, 2026: "Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff". Let's search for this Morgan Stanley downgrade on Novo Nordisk to see the details. But first, let's also pull the `market_view` for NVO to see its financial data.

This is incredibly interesting! Let's examine the news items: 1. **Morgan Stanley Downgrade of Novo Nordisk to Sell:** "Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff" (Sept 12, 2026). The downgrade cites potential market share losses to Eli Lilly's rival offerings over the next 18 months, and the patent cliff. Analyst Thibault Boutherin highlighted this. 2. **Novo Nordisk terminates HERMES and ATHENA trials for ziltivekimab:** "Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’" (Sept 8, 2026). "Novo Nordisk has terminated two additional Phase 3 heart failure studies, HERMES and ATHENA, for its IL-6 inhibitor ziltivekimab, following a previous failure in the ZEUS trial. This decision, based on recommendations from an independent data monitoring committee, indicates IL-6 is an 'invalid target'." Wait, we have an existing slug `novo-nordisk-cardiovascular-pipeline-ziltivekimab` which was created when ziltivekimab failed the ZEUS trial in July 2026. This is a perfect update for that slug! 3. **Wegovy Chinese Approval for MASH:** "Novo Nordisk says Wegovy approved in China for liver disease MASH" (Sept 10, 2026). "Novo Nordisk's weight-loss drug Wegovy has been approved in China for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 RA class drug to receive such approval in the country." 4. **Wegovy STEP Young Pediatric Trial Results:** "Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial" (Sept 8, 2026). "The study, called Step Young, showed that 40.4% of participants were no longer classified as having obesity after 68 weeks of treatment." Let's do some web searches to gather more details on these developments. First, let's search for the Morgan Stanley downgrade on Novo Nordisk. Let's use `web_search`.

Let's fetch the article "Morgan Stanley drops blunt verdict on Ozempic maker" or "Morgan Stanley cuts Novo Nordisk on growth, patent cliff concerns; shares dip" to get details on the downgrade. Let's fetch `https://www.investing.com/news/stock-market-news/morgan-stanley-cuts-novo-nordisk-on-growth-patent-cliff-concerns-shares-dip-4897300`.

This is extremely rich in details. Let's look at the key elements: - Morgan Stanley downgraded Novo Nordisk to Underweight (Sell) from Equal-weight on Sept 11, 2026. - Analyst: Thibault Boutherin. - Price target: 250 Danish crowns (or $40 ADR price target). - Key reasons: - Subdued mid-term growth outlook and concerns over the looming patent cliff for semaglutide (Ozempic/Wegovy) in the early-to-mid 2030s across Europe and the U.S. - Semaglutide accounted for 75% of Novo's sales in 2026, and is modeled to still represent 59% of sales in 2031 when loss-of-exclusivity (LOE) impact begins. - Morgan Stanley forecasts Novo's oral obesity franchise will reach $10 billion in sales by 2031, but "will not be enough to offset pricing and competitive headwinds." - MS's proprietary survey of 200 PCPs pointed to market share losses for Novo over the next 18 months to Eli Lilly's current offerings and its upcoming retatrutide (expected in 2027). - Valuation: Novo trades at 12.5x 2027 estimated earnings, a 7% discount to European large pharma peers but a 35% premium to global peers facing LOE issues (GSK at 10x, Sanofi at 8x). - Upcoming Capital Markets Day: September 21, 2026. Limited scope for major announcements. Wait! We have a note `semaglutide-patent-expirations-generic-competition` (Global Semaglutide Patent Cliff Begins: Novo Nordisk Faces Local Generic Competition in Canada and South Africa) which is highly relevant here, or we can update the main competitive landscape note `glp1-competitive-landscape-ada-2026` or write a new/updated note. Let's see. The patent cliff is specifically about semaglutide. Let's look at `semaglutide-patent-expirations-generic-competition` or `glp1-competitive-landscape-ada-2026`. Let's check the title/content of `semaglutide-patent-expirations-generic-competition`. It discusses international patent expirations in Canada and South Africa. The Morgan Stanley downgrade focuses on the broader semaglutide patent cliff in Europe and the US in the 2030s, as well as competitive market share loss to Eli Lilly. Let's see if we can update `semaglutide-patent-expirations-generic-competition` or `glp1-competitive-landscape-ada-2026` or create a new note. Let's think: the Morgan Stanley downgrade is a major event. It reflects a shifting sentiment on Novo Nordisk's long-term terminal value due to the patent cliff and Lilly's dominance. Let's reuse `semaglutide-patent-expirations-generic-competition` or `glp1-competitive-landscape-ada-2026`. Let's look at `glp1-competitive-landscape-ada-2026` as it represents the overall landscape, or we can update `semaglutide-patent-expirations-generic-competition` to cover the broader US/EU patent cliff and the Morgan Stanley downgrade. Let's check what other notes we have. We have `novo-nordisk-cardiovascular-pipeline-ziltivekimab`. Let's search for the ziltivekimab failure. "Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’" (Sept 8, 2026). "Novo Nordisk has terminated two additional Phase 3 heart failure studies, HERMES and ATHENA, for its IL-6 inhibitor ziltivekimab, following a previous failure in the ZEUS trial." Let's do a search on ziltivekimab, HERMES, and ATHENA to find the details of this termination. Let's use `web_search`.

This is a massive development. Let's summarize the ziltivekimab news: - On September 4, 2026, Novo Nordisk informed investigators that it will halt two Phase 3 trials of ziltivekimab, HERMES and ATHENA, following a recommendation from the independent Data Monitoring Committee (DMC) citing futility (low likelihood of a different outcome than the Phase III ZEUS trial, which missed its primary endpoint in July 2026). - HERMES (NCT05636176) enrolled nearly 4,900 patients with heart failure with preserved or mildly reduced ejection fraction and systemic inflammation. - ATHENA (NCT06200207) enrolled roughly 680 patients to assess heart failure symptoms, quality of life, and physical function. - This is a major blow to Novo's chronic cardiovascular disease strategy and raises questions about IL-6 as a target. Oppenheimer analysts wrote on Tuesday, Sept 8: "IL-6 now looks like an invalid target in chronic cardiovascular disease." - This is the fourth, fifth, and sixth high-profile cardiovascular trial flops in nine weeks (including ZEUS, AstraZeneca/Ionis' Wainua, Novartis' pelacarsen, and Tenax's levosimendan). - Novo Nordisk acquired ziltivekimab through its $725 million upfront acquisition of Corvidia Therapeutics in 2020. - The company will take a non-cash impairment charge in Q3 2026, though it stated this won't affect its 2026 adjusted operating profit guidance. - The only remaining Phase 3 trial for ziltivekimab is ARTEMIS, testing it in the acute setting (post-myocardial infarction), with results expected in H1 2027. Let's update the existing note `novo-nordisk-cardiovascular-pipeline-ziltivekimab` using this detailed, concrete evidence. Wait, let's first check what else we should look up: - What about Structure Therapeutics? Let's do a search for Structure Therapeutics aleniglipron trials, SWITCH or Body Composition trials, or any recent news. - What about Amgen? Let's do a search for Amgen MariTide or any recent updates. - What about Kailera v. Structure Section 1782 discovery ruling? - What about Novo Nordisk v. Eli Lilly ad lawsuit? Let's search for Structure Therapeutics first. Let's use `web_search`.

This is spectacular! Structure Therapeutics (GPCR) filed an 8-K on September 8, 2026, announcing: 1. **72-Week ACCESS Open-Label Extension (OLE) Results for Aleniglipron (GSBR-1290):** - Participants receiving the 180 mg dose achieved up to 16.2% mean body weight reduction at 72 weeks with no observed plateau. - 36% of participants in the highest dose cohorts (90 mg and 120 mg transitioned to 180 mg) achieved >= 20% weight loss. - 77% achieved >= 10% and 60% achieved >= 15% weight loss. - Tolerability was improved by using a lower starting dose of 2.5 mg (titrated every 4 weeks) vs. the 5 mg starting dose in the earlier ACCESS trial. - Discontinuation due to adverse events was under 5% in the OLE (specifically, 2.6% in the 2.5 mg cross-over cohort vs. 11.1% in the ACCESS 120 mg cohort). - No cases of drug-induced liver injury (DILI) and no AST/ALT elevations >= 10x ULN. - Clinically meaningful improvements in cardiometabolic risk factors: Systolic blood pressure (SBP) decreased by up to 12.0 mmHg, diastolic blood pressure (DBP) by up to 6.2 mmHg, waist circumference by up to 15.0 cm, and high-sensitivity C-reactive protein (hsCRP) by up to 64% in the 120 mg arm. - The Phase 3 ACCOMPLISH program commenced in August 2026, comprising ACCOMPLISH-1 (enrolling up to 3,600 patients with obesity/overweight and a comorbidity, HbA1c < 6.5%) and ACCOMPLISH-2 (enrolling up to 1,100 patients with Type 2 diabetes, HbA1c >= 6.5%). - The Phase 3 program will evaluate maintenance doses of 45 mg, 90 mg, and 180 mg, following a 2.5 mg starting dose. - Backed by $1.3 billion in cash (as of June 30, 2026), which is expected to fund the Phase 3 program through 2028. 2. **Positive Phase 1/2a Single Ascending Dose (SAD) Results for ACCG-2671 (Oral Amylin/Calcitonin Receptor Agonist - DACRA):** - This is Structure's oral small molecule amylin candidate. - Demonstrates a long half-life of ~60 hours (supporting potential once-weekly dosing). - Generally well tolerated, no severe adverse events, no DILI. - Encouraging body weight reductions: a single 10 mg dose (n=6) was associated with a mean body weight reduction of 3.3% at Day 24. - Significant target engagement: CTX-1 (a biomarker of bone resorption) decreased by approximately 60% on Day 2 across active dose cohorts, indicating positive bone health engagement. - Phase 2a Multiple Ascending Dose (MAD) 12-week trial is ongoing, with data expected in Q4 2026. - A combination trial evaluating ACCG-2671 in patients receiving a stable dose of an injectable GLP-1 is also planned. This is a massive update for Structure Therapeutics! We have an existing slug `structure-therapeutics-aleniglipron-access-ii-results` (Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway). We can update it with these 72-week ACCESS OLE results and the new oral amylin ACCG-2671 data! Let's do a quick search on the patent litigation between Kailera and Structure Therapeutics or any Section 1782 discovery ruling, to see if there is any update on Case No. 3:2026mc80216. Let's use `web_search`.

Let's search more specifically on google or PACER files for the lawsuit or Section 1782 discovery case between Kailera and Structure Therapeutics. Let's search with `web_search` for `site:dockets.justia.com "Kailera" "Structure"` or `"3:26-mc-80216"` or `"Kailera" "Structure Therapeutics"`.

Ah, the search budget is spent. That is fine, we have a tremendous amount of high-quality, primary, and quantitative evidence for several key themes! Let's review what we have: 1. **Structure Therapeutics (GPCR) 8-K Filing on Sept 8, 2026:** - **Aleniglipron (GSBR-1290) 72-Week ACCESS OLE Results:** - 16.2% mean body weight reduction at 72 weeks for the 180 mg dose. No plateau. - 36% of patients in the highest dose cohorts achieved >= 20% weight loss. - 77% achieved >= 10% and 60% achieved >= 15% weight loss. - 2.5 mg starting dose dramatically improved tolerability (AE-related discontinuations < 5% vs. 11.1% with 5 mg start). - Phase 3 ACCOMPLISH program is underway (ACCOMPLISH-1 and ACCOMPLISH-2), evaluating 45 mg, 90 mg, and 180 mg doses. - Funded by $1.3 billion cash runway through 2028. - **ACCG-2671 (Oral Amylin/Calcitonin Receptor Agonist - DACRA) Phase 1 SAD Results:** - Half-life of ~60 hours, supporting weekly dosing. - 3.3% weight loss at Day 24 with a single 10 mg dose. - 60% decrease in CTX-1 (bone resorption biomarker) on Day 2. - Phase 2a 12-week MAD trial is ongoing (data expected in Q4 2026). - Let's update `structure-therapeutics-aleniglipron-access-ii-results` with this. 2. **Novo Nordisk's Cardiovascular Pipeline - Ziltivekimab Failure:** - **HERMES and ATHENA trials terminated for futility (Sept 4, 2026):** - DMC recommended termination based on futility and low likelihood of a different outcome than ZEUS. - HERMES (NCT05636176) had 4,900 patients with heart failure with mildly reduced/preserved ejection fraction and inflammation. - ATHENA (NCT06200207) had 680 patients. - Oppenheimer: "IL-6 now looks like an invalid target in chronic cardiovascular disease." This removes the "population-selection defense" from the ZEUS failure. - 6 total high-profile cardiovascular flops in 9 weeks. - ARTEMIS is the only remaining Phase 3 trial for ziltivekimab (acute setting post-heart attack), with lower expectations, results in H1 2027. - Q3 2026 non-cash impairment charge. - Let's update `novo-nordisk-cardiovascular-pipeline-ziltivekimab` with this. 3. **Morgan Stanley Downgrade of Novo Nordisk (NVO) to Underweight (Sept 11, 2026):** - Analyst Thibault Boutherin downgraded NVO from Equal-weight to Underweight (Sell) with a price target of 250 DKK / $40 ADR. - Cites the "semaglutide patent cliff on Novo's terminal value" and subdued mid-term growth. - Semaglutide represents 75% of Novo's 2026 sales, and is modeled to represent 59% in 2031 when LOE begins in Europe and the US (early-to-mid 2030s). - Morgan Stanley survey of 200 PCPs points to market share losses over the next 18 months to Eli Lilly (current offerings and upcoming retatrutide in 2027). - Valuation: Novo trades at 12.5x 2027 EPS, a 35% premium to global peers facing LOE issues (GSK at 10x, Sanofi at 8x). - Let's update `semaglutide-patent-expirations-generic-competition` with this major US/EU patent cliff and valuation shift. Let's check if there are any other notes we should write or if we should resolve any threads. Let's look at the open threads/watches: - `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` is still pending as of Sept 14, 2026. The options market was betting on a Sept 11 release but it hasn't dropped yet. We will keep this watch open. - Let's see if any other watch is resolved. Wait, did Amgen start its trials? Amgen's watch is "Amgen plans to initiate three Phase 3 clinical studies evaluating MariTide in people living with Type 2 diabetes by the end of 2026." It is scheduled for late 2026, so it's not resolved yet. Structure Therapeutics' watch: "Structure Therapeutics plans to report topline data from its 44-week Body Composition clinical trial (assessing fat loss) and its 12-week SWITCH clinical trial (assessing transition from injectable GLP-1s to oral aleniglipron) in the fourth quarter of 2026." This is due Q4 2026, so it is not resolved yet. Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation: due end of 2026. Not resolved. Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation: due Jan 1, 2027. Not resolved. Kailera v. Structure Section 1782 Discovery Ruling: due end of 2026. Not resolved. Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads: due end of 2026. Not resolved. Wait, we should write the notes first! Let's write the note for **Structure Therapeutics**: Slug: `structure-therapeutics-aleniglipron-access-ii-results` Let's see if we can update this existing note. The note represents Structure's aleniglipron program and Phase 3 ACCOMPLISH program. This is the perfect slug to update. Let's write the note. Wait, what is the exact title of the existing note? `Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway` Let's write a comprehensive update that incorporates: - The 72-week ACCESS OLE results for aleniglipron (GSBR-1290) showing 16.2% weight loss, no plateau, 36% achieving >= 20% weight loss, and excellent safety/tolerability (AE-related discontinuations < 5% with 2.5 mg starting dose). - The Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 trials that started in August 2026, and how the clinical design is informed by the ACCESS OLE results (using a 2.5 mg starting dose to optimize tolerability and retention). - The positive Phase 1/2a SAD results for ACCG-2671, Structure's oral small molecule amylin candidate (DACRA), showing a 60-hour half-life, 3.3% weight loss with a single 10 mg dose, and significant target engagement (60% CTX-1 bone resorption biomarker reduction). Let's draft the note. Ensure we have verbatim quotes from the 8-K. Quotes: - "Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial" - "ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA)... A single 10 mg dose (n=6) was associated with mean body weight reductions of 3.3% at Day 24. In addition, CTX-1, a well-recognized biomarker of bone resorption, decreased by approximately 60% on Day 2 across the active dose cohorts." Let's call `write_note` for Structure Therapeutics.

Now, let's update the note on ziltivekimab. Slug: `novo-nordisk-cardiovascular-pipeline-ziltivekimab` Title: `Novo Nordisk's Ziltivekimab Fails Phase III ZEUS Trial, Shaking Cardiometabolic and Anti-Inflammatory Pipelines` Let's see: we should update this note to include the early termination of the HERMES and ATHENA trials for futility on September 4, 2026. Let's write a comprehensive update that incorporates: - The September 4, 2026 termination of HERMES and ATHENA trials. - DMC recommendation citing futility and low likelihood of a different outcome than ZEUS. - Details of HERMES (4,900 patients) and ATHENA (680 patients). - Oppenheimer analysts' view that "IL-6 now looks like an invalid target in chronic cardiovascular disease," which removes the "population-selection defense" from the ZEUS failure. - The context of the broader cardiovascular trial slump (6 flops in 9 weeks, including Wainua, pelacarsen, and levosimendan). - Financial impact: Non-cash impairment charge in Q3 2026, though it won't affect full-year adjusted operating profit guidance. - Remaining pipeline: ARTEMIS trial in the acute post-heart attack setting (results expected in H1 2027), though expectations are now lowered. Let's draft the note. Ensure we have verbatim quotes from the sources. Quotes: - "Novo Nordisk is ending two more late-stage studies for its investigational IL-6 inhibitor, citing expected futility and dimming prospects for the class as a whole in cardiovascular disease." - "IL-6 now looks like an invalid target in chronic cardiovascular disease" (Oppenheimer analysts). - "The Danish pharma’s decision to shutter the studies early was 'based on a recommendation from the Data Monitoring Committee on the totality of the data (including the low likelihood of a different outcome from ZEUS)'" Let's call `write_note` for ziltivekimab.

Now let's look at the third major story: **Morgan Stanley Downgrade of Novo Nordisk (NVO) to Underweight on Patent Cliff Concerns and Eli Lilly's Growing Dominance.** Let's see what slug is best to update or if we should write a new note. We have `semaglutide-patent-expirations-generic-competition` (Global Semaglutide Patent Cliff Begins: Novo Nordisk Faces Local Generic Competition in Canada and South Africa). The Morgan Stanley downgrade specifically focuses on the long-term semaglutide patent cliff in Europe and the US in the early 2030s and how it impacts Novo's terminal value, as well as the immediate market share loss to Eli Lilly over the next 18 months. Wait, let's look at `semaglutide-patent-expirations-generic-competition` as a durable subject. It is about the semaglutide patent cliff and generic competition. The Morgan Stanley downgrade is the first major Wall Street sell-side research piece that frames the long-term semaglutide patent cliff as a primary driver of a "Sell" (Underweight) rating on the stock, modeling its impact on Novo's terminal value. This is a perfect, highly relevant update for this slug! Let's update `semaglutide-patent-expirations-generic-competition`. Wait, let's read the preview or check what is currently in `semaglutide-patent-expirations-generic-competition`. The existing note is: `Global Semaglutide Patent Cliff Begins: Novo Nordisk Faces Local Generic Competition in Canada and South Africa`. Let's update it to cover: - Morgan Stanley's downgrade of Novo Nordisk (NVO) to Underweight (Sell) on September 11, 2026. - Analyst Thibault Boutherin's assessment of the "semaglutide patent cliff on Novo’s terminal value." - The fact that semaglutide accounts for 75% of Novo's sales in 2026, and is modeled to still represent 59% in 2031 when the loss-of-exclusivity (LOE) begins across Europe and the US (early-to-mid 2030s). - The projection that Novo's oral obesity franchise will reach $10 billion in sales by 2031, but "will not be enough to offset pricing and competitive headwinds." - The findings from Morgan Stanley's proprietary survey of 200 primary care physicians (PCPs), pointing to market share losses for Novo over the next 18 months to Eli Lilly's current offerings (Mounjaro/Zepbound) and its upcoming retatrutide (expected in 2027). - Valuation multiples: NVO trades at a 35% premium to global peers facing their own LOE issues (GSK at 10x, Sanofi at 8x), which MS argues is unjustified given the looming cliff. - Let's anchor this in the current public-markets data from the `market_view` of NVO (trades at $43.07, representing a P/E of 10.53, down 9.3% over the past 5 days, market cap $190.32B). Let's write this update. Ensure we carry verbatim quotes from the Morgan Stanley report (via the Investing.com article). Quotes: - "Novo’s valuation 'not entirely' reflects subdued mid-term growth and 'the implications of the semaglutide patent cliff on Novo’s terminal value.'" - "Semaglutide accounted for 75% of Novo’s sales in 2026, and will face a large patent cliff in the early-to-mid 2030s across Europe and the U.S." - "The bank forecasts Novo’s oral obesity franchise will reach $10 billion in sales by 2031 but said this 'will not be enough to offset pricing and competitive headwinds.'" Let's call `write_note` for the patent cliff note.

This is incredible. We have successfully written and updated three major findings with high precision, deep details, verbatim quotes, and direct citations. Let's do a quick final check of our threads and watches: - We reviewed the active watches and threads. None of them have fired yet: - Viking's Phase 1 maintenance study readout is still pending (expected in Q3 2026, highly anticipated). - Viking's Oral Phase 3 start is expected in Q4 2026. - Structure's Body Composition and SWITCH trials are expected in Q4 2026. - Novo's list price cuts are scheduled for Jan 1, 2027. - Court cases (Kailera v. Structure, Novo v. Lilly ad lawsuit) are scheduled for late 2026. - Amgen's trials and IRS tax court ruling are expected in late 2026. - Since none of these have fired, we do not call `record_event`. We leave them open for future cycles to monitor. - We do not need to create any new threads or watches, as the existing ones perfectly cover the forward-looking catalysts. Let's call `finish_cycle` to complete this research cycle!

I have completed the research cycle on the commercial and competitive dynamics of GLP-1 receptor agonist drugs and their industry-wide ripple effects. Here is a summary of the key findings and updates from this cycle: ### 1. Structure Therapeutics (GPCR) Reports Strong 72-Week aleniglipron & Oral Amylin Data * **Aleniglipron (GSBR-1290) 72-Week ACCESS OLE Results:** Structure Therapeutics reported that patients on the 180 mg dose achieved a **16.2% mean body weight reduction at 72 weeks** with no observed plateau. Crucially, the implementation of a lower **2.5 mg starting dose** (titrated every 4 weeks) dramatically improved tolerability, dropping treatment discontinuation rates due to adverse events to **under 5%** (compared to 11.1% in the initial 120 mg ACCESS cohort). Clinically meaningful improvements were also seen in cardiometabolic risk factors, including a **12.0 mmHg reduction in systolic blood pressure** and a **64% decrease in high-sensitivity C-reactive protein (hsCRP)**. These data support the ongoing Phase 3 ACCOMPLISH program. * **ACCG-2671 (Oral Amylin/Calcitonin Receptor Agonist - DACRA) Phase 1 SAD Results:** This oral small-molecule candidate demonstrated a long half-life of **~60 hours**, supporting a weekly dosing profile. A single 10 mg dose drove a **3.3% weight loss at Day 24** and a **60% decrease in CTX-1** (a biomarker of bone resorption) on Day 2, indicating strong target engagement and bone-preservation benefits. * **Update:** Updated the existing note `[[structure-therapeutics-aleniglipron-access-ii-results]]`. ### 2. Novo Nordisk Terminates Two Phase III Cardiovascular Studies of Ziltivekimab * **Futility Halted:** On **September 4, 2026**, Novo Nordisk informed investigators that it is prematurely ending the Phase III **HERMES** (NCT05636176, ~4,900 patients) and **ATHENA** (NCT06200207, ~680 patients) heart failure trials of its IL-6 inhibitor antibody, **ziltivekimab**. The independent Data Monitoring Committee concluded that both trials were highly unlikely to succeed, following the drug's earlier failure in the ZEUS trial in July 2026. * **IL-6 Target Questioned:** Oppenheimer analysts noted that **"IL-6 now looks like an invalid target in chronic cardiovascular disease,"** removing the population-selection defense that initially shielded the ZEUS results. This represents the fifth and sixth high-profile cardiovascular trial flops across the industry in a span of nine weeks. Novo Nordisk will take a non-cash impairment charge in Q3 2026. * **Update:** Updated the existing note `[[novo-nordisk-cardiovascular-pipeline-ziltivekimab]]`. ### 3. Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight on Patent Cliff Concerns * **Looming Patent Cliff:** On **September 11, 2026**, Morgan Stanley downgraded Novo Nordisk from Equal-weight to Underweight (Sell) with a price target of 250 DKK ($40 ADR). Morgan Stanley highlighted that semaglutide represents **75% of Novo's 2026 sales** and will still represent **59% of sales in 2031**, right as loss-of-exclusivity (LOE) impacts begin across Europe and the US in the early-to-mid 2030s. * **Market Share Losses:** MS's proprietary survey of 200 primary care physicians points to market share losses for Novo over the next 18 months to Eli Lilly's current offerings and its upcoming triple-agonist **retatrutide** (expected in 2027). The bank warns that Novo's oral obesity pipeline (modeled at $10 billion in sales by 2031) will not be enough to offset these steep pricing and competitive headwinds. * **Market Impact:** Novo Nordisk shares declined **9.3% over a five-day period** to close at **$43.07** ([Novo Nordisk Market View](/markets/NVO/2026/09/14)), compressing its market cap to **$190.32 billion**—widening the valuation gap against Eli Lilly's **$994.92 billion** market cap ([Eli Lilly Market View](/markets/LLY/2026/09/14)). * **Update:** Updated the existing note `[[semaglutide-patent-expirations-generic-competition]]`. All active watches for the upcoming catalysts (such as Viking's imminent Q3 2026 maintenance study readout, Viking's and Structure's Q4 clinical starts/readouts, and late-2026 legal rulings) remain active and will be monitored in future cycles.